Emma Cartmell Appointed to CherryCircle Board of Directors

CherryCircle, announced the appointment of Emma Cartmell to its board of directors. Cartmell, a renowned healthcare industry advisor and investor, will help shepherd the company through a new stage of strategy and growth following its recent Series Seed investment round.

CherryCircle is a software company developing the QbDVisionTM software platform to accelerate pharmaceutical manufacturing process development.

“CherryCircle’s QbDVision solution is the type of innovation the pharmaceutical industry needs,” said Cartmell. “I believe in their vision to reduce the amount of time and expense it takes to bring drugs and medical devices to market and this team has the experience to make it happen.”

Cartmell also serves on the boards of the following companies and industry associations: HIMSS North America (non-profit), Austin Healthcare Council (non-profit), Morgan Stanley’s Equity Expansion Fund and multiple leading healthcare companies, including Medsphere, B.Well, Care.Coach and Accordion Health (acquired in 2017). As a founding partner in Exsede Healthcare Consulting, she guided emerging technology companies focused on precision medicine, health analytics, information technology, and wellness through processes that included capital acquisition, growth strategy creation, and partnership development.

In 2013, Ms. Cartmell was appointed as an advisor to both the U.S. and British governments on healthcare technology trade and investment, and she presents regularly at Health DataPalooza, ATA and HIMSS on the international venture capital market for digital health. In 2017 Ms. Cartmell was awarded the John. A Page Outstanding Service Award at HIMSS17 for her leadership in HIMSS and the Healthcare Industry. She is a native of the UK and a resident of Austin, Texas.

“We are beyond excited to welcome Emma to our board of directors,” said Yash Sabharwal, President and CEO, CherryCircle Software. “The depth and breadth of her knowledge and experience will be invaluable as we seek to change the way the pharma industry thinks about the manufacturing lifecycle. She brings strategic insight that will be critical to the success of our mission in an industry undergoing transformation.”

WE WELCOME YOUR VIEWS

Please enter your comment!
Please enter your name here